Circio Holding ASA (”Circio” or ”the Company”) announced, on the 1st of June 2026, a research collaboration with GenAssist Ltd (”GenAssist”), a Suzhou-based biotechnology company developing tissue-specific AAV delivery technology. The parties will combine GenAssist’s tissue-targeted, liver-de-targeting capsids and promoters with Circio’s circVec expression cassette to develop next-generation AAV vectors. The collaboration pursues two distinct objectives: high muscle-specific expression at substantially reduced systemic doses for genetic muscle disease, and joint in vivo CAR-T candidates built on GenAssist’s T-cell-targeting capsids for oncology and autoimmune applications. No financial terms are disclosed.
In summary, Analyst Group regards the GenAssist collaboration as a substantive addition to Circio’s 2026 partnership activity, combining a delivery asset with comparatively advanced preclinical data, entry into muscle as a new high-value indication, and exposure to both of Circio’s development tracks within a single agreement. That said, no financial terms have been disclosed, and both programmes are at an early preclinical stage where translational risk is the dominant variable. Weighing these factors, Analyst Group assesses that the collaboration adds another interesting partner to circVec’s delivery network and further supports the platform’s licensing appeal.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.